Medical therapy for nonalcoholic fatty liver disease in children and adolescents

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 1, 2012, Pages 1-3

  Andrews, Danielle B ^a   Lavine, Joel E ^b  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

fatty liver disease; metabolic syndrome; nonalcoholic steatohepatitis; obesity; TONIC

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; METFORMIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHILD HEALTH CARE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; EDITORIAL; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER HISTOLOGY; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATIENT ASSESSMENT; STEATOSIS;

ADOLESCENT; BIOPSY; CHILD; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; METFORMIN; VITAMIN E; VITAMINS;

EID: 83455236263     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.72     Document Type: Editorial

References (16)

1. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50, 1282-1293 (2009)
2. Schwimmer J, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388-1393 (2006)
3. Schwimmer J, Behling C, Newbury R, Deutsch R, Schork N, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42, 641-649 (2005)
4. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58, 1538-1544 (2009)
5. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118, 277-283 (2008)
6. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr. 136, 734-738 (2000)
7. Schwimmer JB, Middleton M, Deutsch R, Lavine JE. A Phase 2 clinical trial of metformin as a treatment for non-diabetic pediatric nonalcoholic steatohepatitis. Aliment Pharmacol. Ther. 21, 871-879 (2005)
8. Dohil R, Schmeltzer S, Cabrera B, et al. Pilot study: enteric-coated cysteamine for the treatment of pediatric nonalcoholic fatty liver disease. Aliment Pharmacol. Ther. 33, 1036-1044 (2011)
9. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48, 119-128 (2008)
10. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 114, 8424-8445 (1998)
11. Patton HM, Lavine JE, Van Natta ML, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis (NASH). Gastroenterology 135, 1961-1971 (2008)
12. Lavine JE, Schwimmer JB, Molleston JP, et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp. Clin. Trials 31, 62-70 (2010)
13. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005)
14. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305(16), 1659-1668 (2011)
15. Sanyal AJ, Chalasani N, Kowdley K, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010)
16. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54(1), 344-353 (2011)